Tagged with oncology,

Luxembourg Marc Diederich, Director of the LBMCC and principal investigator conducting independent research, leading and training a 25-person group including PhD and MSc students, runs us through the raison d’être of the Laboratory, how it is dedicated to the study of the cell and molecular biology of cancer and is focused…

Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…

Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…

Pharma Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and  the development path he will follow in order to foster growth. You took over the helm of the Mexican affiliate of…

Pharma Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de Elizalde reveals the key pillars that will drive the affiliate to new heights. In Mexico, generics make up 79 percent…

Healthcare The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges and prospects of medical innovation in the country. Can you please provide an insight into the history and presence of…

Pharma György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of budget constraints as well his work founding the Hungarian Society of Clinical Oncology. As an introduction to our readers could…

Pharma Oncology already represents the second largest portion of Egypt’s public healthcare budget, and despite limited public funding, demand for and acceptance of innovation is high, according to Roche’s regional general manager Ehab Yousef. As general manager for the Middle East sub-region at Roche, how would you assess demand for and…

Pharma Frédéric Duchesne, President & CEO of Pierre Fabre’s pharmaceuticals division, talks about the the four main pillars at the heart of Trajectoire 2018, a strategic plan approved in December 2014: improving competitiveness, renewing innovative capabilities, increasing operational excellence, and lastly, furthering international development. Mr Duchesne also reveals how in 2015…

Pharma After choosing Egypt as the first country to host a production plant in the Middle East, AstraZeneca is interested in strengthening its foothold in the market. The country president discusses the challenges the company is facing as well as the initiatives in place to increase market access and affordability. Could…

Pharma Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders to adopt the positive and collaborative attitude that will ensure Dutch patients can still expect to access the most innovative…

Pharma Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer specifically to engage the government in the development of a more sustainable healthcare system. To start off, we are approaching…